Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail.

Recent News:

 

8/11/2014 HEMISPHERX BIOPHARMA ANNOUNCES FINANCIAL RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2014
. . . Receives New U.S. Composition of Matter Patent Covering Ampligen(R) Formulations


8/4/2014 Hemispherx’s Two Drugs, Ampligen® and Alferon® Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses
……New Publication Compares Achievable Concentrations in Humans of Various Interferons and Other Potential Drug Treatments


7/22/2014 Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to Other Drugs
……New Report Compares Achievable Concentrations of Various Candidate Treatments in Humans; CDC Issues New Guidelines for Protections


7/14/2014 Hemispherx Biopharma and Bioclones, A Leading South African Biotechnology Company, Join Forces on Novel Therapeutic Cancer Vaccine
… Builds on Recently Issued Patent Estates of Both Companies and Basic Research / Clinical Advancement in Cancer Control


7/8/2014 Hemispherx Biopharma and Bioclones Join Forces in Effort to Eradicate HIV/AIDS Virus Based on Recent Clinical Insights of Wistar Institute, University of Pennsylvania
…Patients Receiving Alpha Interferon May Go Into Long Term Remission After Initial HAART (Highly Active Anti-retroviral Therapy) Therapy is Discontinued


More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP

 

Investor Relations:

Charles Jones
CJones & Associates Public Relations
888-557-6480
cjones@cjonespr.com